MedTrace Logo

Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis

NCT02116634 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2016-01-14

No results posted yet for this study

Summary

Whether the mesenchymal injection on ALS patients is effective or not?

Conditions

Interventions

BIOLOGICAL

mesenchymal stem cell

intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline

Sponsors & Collaborators

  • Alzahra Hospital, Iran

    lead OTHER

Principal Investigators

  • keivan basiri, MD · Isfahan neurosciences research center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02116634 on ClinicalTrials.gov